Integrated biomarker study of metabolic syndrome in pregnant women with HIV on DTG-based ART
Official title: Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)
Funded at Johns Hopkins University · NIH-11593952 · Data updated 2026-11-12
Researchers will look for biological signs in pregnant women with HIV on a DTG-based regimen to understand why weight gain and metabolic problems happen and how these affect pregnancy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 5, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $32,616 |
| NIH project number | 3DP1HD115433-03S3 |
| Project ID | NIH-11593952 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant women living with HIV who are on or starting Dolutegravir-based ART at participating sites in the US or Nigeria.
✕Less likely to help
Pregnant patients not on DTG-based ART or outside the study sites may not directly benefit from this research.
What this research studies
This project follows pregnant people living with HIV who are using a DTG-based ART regimen to uncover biological markers linked to weight gain and metabolic syndrome. It will collect proteomic and metabolomic data from participants across four sites in the United States and Nigeria, and relate these markers to pregnancy outcomes. The study uses a prospective cohort design and taps into NIH infrastructure to analyze how DTG-based ART may influence metabolism during and after pregnancy. Findings could help tailor safer treatment strategies for pregnant patients with HIV.
Why it matters
Potential benefit: If successful, the research could improve understanding of why DTG-based ART leads to weight gain and metabolic issues in pregnancy, potentially guiding safer treatment choices for pregnant people with HIV.
How similar studies have gone: Previous studies have linked DTG-based ART to weight changes and metabolic effects, but this project aims to clarify mechanisms with an integrated biomarker approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Eke, Ahizechukwu C. — Johns Hopkins University
- Study coordinator: Eke, Ahizechukwu C.
Related research
Other NIH-funded projects on the same topics.
-
Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on DTG-based ART
This project looks at why some pregnant women living with HIV on a common DTG-based therapy gain weight or develop metabolic problems, by studying their proteins and metabolites across four sites in the US and Nigeria.
-
Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on DTG-based therapy
This project looks at markers in pregnant women living with HIV who are on a DTG-containing regimen to understand why some develop metabolic problems during pregnancy.
-
Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on a DTG-based regimen
Researchers will study blood and metabolite markers in pregnant women with HIV on a DTG-based regimen to understand why weight gain and metabolic problems may occur during pregnancy.
-
Understanding metabolic syndrome in pregnant women with HIV on specific treatments
This study is looking at how a specific HIV treatment called Dolutegravir affects weight gain and overall health in pregnant women with HIV, to help understand any health challenges they might face during pregnancy.
-
Choline for fetal brain protection in pregnant women who drink heavily
Giving choline to pregnant women who drink heavily may help protect the baby’s brain and improve early development.
-
Mentor Moms+: a community-led plan to cut alcohol use and HIV risk during pregnancy in South Africa
A community-based program adapts a trusted peer-led model to help pregnant and lactating people reduce alcohol use and HIV risk in South Africa.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.